Similar articles

• Pharmacological properties of substituted gamma-butyrolactones. I. The effects on the central nervous system.

  Sieroslawska J, Hano J, Sypniewska M, Czarnecki R, Chojnacka-Wójcik E, Harasiewicz A. Sieroslawska J, et al. Pol J Pharmacol Pharm. 1973 Jan-Feb;25(1):1-16. Pol J Pharmacol Pharm. 1973. PMID: 4798097 No abstract available.
• The central action of 5-allyl-5-(beta-hydroxypropyl)-N-phenylbarbituric acid and the corresponding lactone.

  Sieroslawska J, Czarnecki R, Sypniewska M, Chojnacka-Wójcik E. Sieroslawska J, et al. Pol J Pharmacol Pharm. 1973 Mar-Apr;25(2):113-26. Pol J Pharmacol Pharm. 1973. PMID: 4798099 No abstract available.
• [Longitudinal profiles of the effects of psychotropic drugs. Animal experimental findings].

  Kreiskott H. Kreiskott H. Arzneimittelforschung. 1974 Jul;24(7):974-6. Arzneimittelforschung. 1974. PMID: 4408071 German. No abstract available.
• A rational framework for the development, evaluation, and use of psychoactive drugs.

  Irwin S. Irwin S. Am J Psychiatry. 1968 Feb;124(8):Suppl:1-19. doi: 10.1176/ajp.124.8S.1. Am J Psychiatry. 1968. PMID: 4865729 Review. No abstract available.
• Behavioral pharmacology and toxicology.

  Weiss B, Laties VG. Weiss B, et al. Annu Rev Pharmacol. 1969;9:297-326. doi: 10.1146/annurev.pa.09.040169.001501. Annu Rev Pharmacol. 1969. PMID: 4892430 Review. No abstract available.